Sermorelin

Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce growth hormone naturally. It was developed as a diagnostic tool and later explored for treating age-related decline in growth hormone levels.

Sermorelin research applications relate to its ability to change body composition by reducing visceral fat, which is the fat found around the internal organs, such as the kidneys. Visceral fat is associated with ill health effects, such as cardiovascular disease. Areas studied include: Age-related growth hormone decline; Improving sleep quality and recovery after workouts; General metabolic health.

Sermorelin binds to GHRH receptors on the pituitary gland, triggering pulsatile growth hormone release. This approach preserves the body’s natural feedback systems, unlike direct growth hormone injections.

Side effects in the research setting include injection site reactions, fluid retention, and mild joint discomfort.

One commonly referenced research protocol is: Week 1: 100 mcg (0.1 mg) daily; Week 2: 200 mcg (0.2 mg) daily; Week 3 and beyond: 300 mcg (0.3 mg) daily. Shown for education only; a licensed clinician should set any actual dose. See the dosing table.

Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.

There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.

Sermorelin was previously FDA-approved in the US but is no longer marketed as an approved drug (status as of October 2026).